山西微创痔疮手术费用山西中医院痔疮比较好,太原肛周脓肿为什么会复发,太原痔疮复发,山西外痔疮的手术费用,太原痔疮出血多少算正常,山西什么医院的痔疮科好,山西大便出血鲜红

LOS ANGELES, May 29 (Xinhua) -- Nineteen percent of

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.

LOS ANGELES, May 5 (Xinhua) -- NASA has selected three planetary missions from which it will pick one potential mission to look at Mars' interior for the first time, NASA's Jet Propulsion Laboratory (JPL) announced on Thursday.The Mars mission, to be launched in 2016, would be led by JPL, according to the announcement.The other two missions would study an extraterrestrial sea on one of Saturn's moons; or study in unprecedented detail the surface of a comet's nucleus, said JPL in Pasadena, Los Angeles.The selected investigations could reveal much about the formation of our solar system and its dynamic processes, JPL said.Each mission will receive three million dollars to conduct its mission's concept phase or preliminary design studies and analyses, JPL said in a news release.After another detailed review in 2012 of the concept studies, NASA will select one to continue development efforts leading up to launch. The selected mission will be cost-capped at 425 million dollars, not including launch vehicle funding, according to JPL.NASA's Discovery Program requested proposals for spaceflight investigations in June 2010. A panel of NASA and other scientists and engineers reviewed 28 submissions."NASA continues to do extraordinary science that is re-writing textbooks," said NASA Administrator Charles Bolden. "Missions like these hold great promise to vastly increase our knowledge, extend our reach into the solar system and inspire future generations of explorers."

SAN FRANCISCO, April 25 (Xinhua) -- Oracle Corp. on Monday announced that its co-president Safra Catz is taking the additional position as the software giant's chief financial officer (CFO), following the resignation of its current CFO Jeff Epstein.Epstein was named Oracle's CFO in September 2008, and had reported directly to Catz. Oracle didn't give details about Epstein's departure.Catz joined Oracle in April 1999 and has been its president since January 2004. She previously served as the company's CFO from November 2005 to September 2008."Safra already has the long-standing confidence of our employees, our Board and our shareholders," Oracle's chief executive officer Larry Ellison said in a statement, adding that " there is no more logical choice for CFO.""The CFO function has reported to Safra for a number of years and she's acted as Oracle's CFO in the past. She has the full support of the Board," noted Jeff Henley, chairman of Oracle's board of directors.

BEIJING, May 12 (Xinhuanet) -- Italian archaeologists are digging the remains of Lisa Gherardini, a 16th-century woman who is widely believed to be the model for the famous portrait Mona Lisa, AFP reported on Wednesday.The team of historians say they will try to find the remains using geo-radar equipment and then try to re-create a likeness of what the woman, Lisa Gherardini, would have looked like to compare her to Leonardo Da Vinci's Mona Lisa.Gherardini (1479-1542), also known by her married name as Lisa del Giocondo, was the wife of a Florentine silk merchant and is widely believed to have been the model for the  portrait that now hangs in the Louvre in Paris.But the issue has never been settled definitively and mystery still shrouds the model's enigmatic expression and other details of the portrait.